WO2008035359A3 - Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque - Google Patents

Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque Download PDF

Info

Publication number
WO2008035359A3
WO2008035359A3 PCT/IN2007/000226 IN2007000226W WO2008035359A3 WO 2008035359 A3 WO2008035359 A3 WO 2008035359A3 IN 2007000226 W IN2007000226 W IN 2007000226W WO 2008035359 A3 WO2008035359 A3 WO 2008035359A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
oximinophenoxyalkanoic
phenylalkanoic
derivatives
preparation
Prior art date
Application number
PCT/IN2007/000226
Other languages
English (en)
Other versions
WO2008035359A2 (fr
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Harikishore Pingali
Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Ltd
Braj Bhushan Lohray
Vidya Bhushan Lohray
Harikishore Pingali
Pankaj Ramanbhai Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd, Braj Bhushan Lohray, Vidya Bhushan Lohray, Harikishore Pingali, Pankaj Ramanbhai Patel filed Critical Cadila Healthcare Ltd
Publication of WO2008035359A2 publication Critical patent/WO2008035359A2/fr
Publication of WO2008035359A3 publication Critical patent/WO2008035359A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/52—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un acide oxyminophénoxyalcanoïque et l'acide phénylalcanoïque de la formule générale (I) leurs formes tautomères, leurs stéréoisomères, leurs sels pharmaceutiquement acceptables, les compositions pharmaceutiques les contenant, leurs procédés de préparation, l'utilisation de ces composés en médicine et les intermédiaires impliqués dans leur préparation.
PCT/IN2007/000226 2006-06-12 2007-06-05 Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque WO2008035359A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN913MU2006 2006-06-12
IN913/MUM/2006 2006-06-12
IN2167/MUM/2006 2006-12-29
IN2167MU2006 2006-12-29

Publications (2)

Publication Number Publication Date
WO2008035359A2 WO2008035359A2 (fr) 2008-03-27
WO2008035359A3 true WO2008035359A3 (fr) 2008-05-15

Family

ID=39032144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000226 WO2008035359A2 (fr) 2006-06-12 2007-06-05 Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque

Country Status (1)

Country Link
WO (1) WO2008035359A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2010049946A2 (fr) * 2008-10-27 2010-05-06 Cadila Healthcare Limited Ligands des récepteurs thyroïdiens
ES2403120T3 (es) 2008-12-24 2013-05-14 Cadila Healthcare Limited Nuevos derivados de oxima
JP2012116753A (ja) * 2009-03-26 2012-06-21 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤活性化受容体の活性化剤
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AP2013006987A0 (en) * 2010-12-28 2013-07-31 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2014192023A1 (fr) * 2013-05-22 2014-12-04 Cadila Healthcare Limited Nouveaux composés appropriés pour le traitement de la dyslipidémie
US20160083380A1 (en) * 2013-12-16 2016-03-24 Cadila Healthcare Limited Oximino derivatives for the treatment of dyslipidemia
KR20200072795A (ko) * 2018-12-13 2020-06-23 고려대학교 산학협력단 옥시이미노메틸벤젠 유도체를 유효성분으로 포함하는 일주기 연관성 질환의 예방 또는 치료용 약학적 조성물
KR102209201B1 (ko) * 2020-06-29 2021-02-01 고려대학교 산학협력단 옥시이미노메틸벤젠 유도체

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003430A1 (de) * 1969-01-31 1970-09-03 Fournier Gmbh Lab Phenoxy-alkyl-carbonsaeurederivate
GB1352723A (en) * 1970-09-10 1974-05-08 Merck & Co Inc 2-phenyl-benzoxazoles and their production and use
DE2065956A1 (de) * 1969-01-31 1977-07-14 Fournier Gmbh Lab P-acyloxim-phenoxyessigsaeuren und ihre derivate, ihre herstellung sowie pharmazeutische mittel
EP0002666A1 (fr) * 1977-11-21 1979-07-11 Hoechst Aktiengesellschaft Acides 1,2-benzisoxazolyloxy (ou thio) acétiques et dérives apparentés, leurs procédés de préparation et médicaments les contenant
US4259509A (en) * 1977-02-14 1981-03-31 Albert Rolland S.A. 2-Methyl-2-phenoxy-propionic acid derivatives, process for their preparation and therapeutical applications thereof
US4999345A (en) * 1988-06-04 1991-03-12 Basf Aktiengesellschaft Sulfonamide derivatives and drugs obtained therefrom
EP0656348A2 (fr) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Dérivés d'acide acérique comme médicaments
WO1995019976A1 (fr) * 1994-01-25 1995-07-27 Biocode S.A. Derives chemoluminescents heterocycliques
US6355796B1 (en) * 1999-02-16 2002-03-12 Basf Aktiengesellschaft Processes and intermediate compounds for the preparation of 2-(N,N-disubstituted) amino-4-(perfluoroalkyl)-1, 3- oxazin-6-one and 6-(perfluoroalkyl) uracil compounds
WO2002096894A1 (fr) * 2001-05-31 2002-12-05 Glaxo Group Limited Derives de thiazole ou d'oxazole pouvant etre utilises dans le traitement des maladies cardiovasculaires et apparentees
US6518290B1 (en) * 1999-12-02 2003-02-11 Michael Lawrence Sierra Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
EP1310494A1 (fr) * 2000-08-11 2003-05-14 Nippon Chemiphar Co., Ltd. ACTIVATEURS DE PPAR (delta)
WO2005035495A2 (fr) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Antagonistes du recepteur du fibrinogene et leur utilisation
WO2005113519A1 (fr) * 2004-05-14 2005-12-01 Irm Llc Composes et compositions en tant que modulateurs de ppar
WO2006011669A1 (fr) * 2004-07-28 2006-02-02 Santen Pharmaceutical Co., Ltd. Nouveaux composés apparentés à l'acide cinnamique
WO2007028424A1 (fr) * 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Dérivés d'amides en tant qu’activateurs de ppar

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2003430A1 (de) * 1969-01-31 1970-09-03 Fournier Gmbh Lab Phenoxy-alkyl-carbonsaeurederivate
DE2250327A1 (de) * 1969-01-31 1973-04-26 Fournier Gmbh Lab Neue phenoxycarbonsaeurederivate, ihre herstellung sowie diese enthaltende pharmazeutische mittel
DE2065956A1 (de) * 1969-01-31 1977-07-14 Fournier Gmbh Lab P-acyloxim-phenoxyessigsaeuren und ihre derivate, ihre herstellung sowie pharmazeutische mittel
GB1352723A (en) * 1970-09-10 1974-05-08 Merck & Co Inc 2-phenyl-benzoxazoles and their production and use
US4259509A (en) * 1977-02-14 1981-03-31 Albert Rolland S.A. 2-Methyl-2-phenoxy-propionic acid derivatives, process for their preparation and therapeutical applications thereof
EP0002666A1 (fr) * 1977-11-21 1979-07-11 Hoechst Aktiengesellschaft Acides 1,2-benzisoxazolyloxy (ou thio) acétiques et dérives apparentés, leurs procédés de préparation et médicaments les contenant
US4999345A (en) * 1988-06-04 1991-03-12 Basf Aktiengesellschaft Sulfonamide derivatives and drugs obtained therefrom
EP0656348A2 (fr) * 1993-12-03 1995-06-07 F. Hoffmann-La Roche Ag Dérivés d'acide acérique comme médicaments
WO1995019976A1 (fr) * 1994-01-25 1995-07-27 Biocode S.A. Derives chemoluminescents heterocycliques
US6355796B1 (en) * 1999-02-16 2002-03-12 Basf Aktiengesellschaft Processes and intermediate compounds for the preparation of 2-(N,N-disubstituted) amino-4-(perfluoroalkyl)-1, 3- oxazin-6-one and 6-(perfluoroalkyl) uracil compounds
US6518290B1 (en) * 1999-12-02 2003-02-11 Michael Lawrence Sierra Substituted oxazoles and thiazoles derivatives as HPPAr alpha activators
EP1310494A1 (fr) * 2000-08-11 2003-05-14 Nippon Chemiphar Co., Ltd. ACTIVATEURS DE PPAR (delta)
WO2002096894A1 (fr) * 2001-05-31 2002-12-05 Glaxo Group Limited Derives de thiazole ou d'oxazole pouvant etre utilises dans le traitement des maladies cardiovasculaires et apparentees
WO2005035495A2 (fr) * 2003-10-08 2005-04-21 Nicholas Piramal India Limited Antagonistes du recepteur du fibrinogene et leur utilisation
WO2005113519A1 (fr) * 2004-05-14 2005-12-01 Irm Llc Composes et compositions en tant que modulateurs de ppar
WO2006011669A1 (fr) * 2004-07-28 2006-02-02 Santen Pharmaceutical Co., Ltd. Nouveaux composés apparentés à l'acide cinnamique
WO2007028424A1 (fr) * 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Dérivés d'amides en tant qu’activateurs de ppar

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
AKERBLOM, E.B. ET AL.: "Six new photolabile linkers for solid-phase synthesis. 1. Methods of preparation", MOLECULAR DIVERSITY, vol. 3, 1998, pages 137 - 148, XP002472861 *
BORSCHE, W. ET AL.: "Über Kern-acylierungen nach Friedel-Crafts. III", JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 553, 1942, pages 260 - 277, XP009097086 *
DE LUCA, L. ET AL.: "A new supported reagent for the photochemical generation of radicals in solution", ORG. LETT., vol. 3, no. 6, 2001, pages 855 - 857, XP002472862 *
DUBOIS, G.E. ET AL.: "Dihydrochalcone Sweeteners. A study of the Atypical Temporal Phenomena", J. MED. CHEM., vol. 24, no. 4, 1981, pages 408 - 428, XP002345673, ISSN: 0022-2623 *
LI, G. ET AL.: "Synthesis of novel phenoxy-linked diazirine glycero- and sphingolipid probes via trialkylaryltin intermediates", TETRAHEDRON LETTERS, vol. 41, no. 35, 2000, pages 6737 - 6741, XP004213940 *
MASSOLINI, G. ET AL.: "SULL'ATTIVITÀ ANTIFUNGINA FITOIATRICA DI ALCUNE BENZOFENONOSSIME", IL FARMACO, ED. SC., vol. 42, no. 2, 1987, pages 117 - 124, XP002047980, ISSN: 0014-827X *
PLATTNER, J. J. ET AL.: "[(AMINOMETHYL)ARYLOXY]ACETIC ACID ESTERS. A NEW CLASS OF HIGH- CEILING DIURETICS. 3. VARIATION IN THE BRIDGE BETWEEN THE AROMATIC RINGS TO COMPLETE MAPPING OF THE RECEPTOR", J. MED. CHEM., vol. 28, no. 1, 1985, pages 79 - 93, XP002022320, ISSN: 0022-2623 *
SAWADA, S. ET AL.: "Improved synthesis of 4-[(R,S)-1-[1-(9H-fluoren-9yl)-methoxycarbonylamino]-(2',4'-dimethoxybenzyl]phenoxyacetic acid as a peptide-resin linker in the solid-phase synthesis of peptide-amides", BIOSCI. BIOTECH. BIOCHEM., vol. 56, no. 9, 1992, pages 1506 - 1507, XP002472860 *
TORRES Y GONZALES, C.: "No. 143. Sur quelques benzhydrylamines para-alcoxylées", BULL. SOC. CHIM. FR, vol. 37, no. 4, 1925, pages 1591 - 1596, XP009097132 *
YOSHIDA, N. ET AL.: "Synthesis of antiinflammatory compounds. I. Synthesis and antiinflammatory activity of phenyl-substituted pyrrole derivatives", YAKUGAKU ZASSHI, vol. 93, no. 5, 1973, pages 584 - 598, XP009097090 *

Also Published As

Publication number Publication date
WO2008035359A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2008035359A3 (fr) Acide oxyminophénoxyalcanoïque et dérivés de l'acide phenylalcanoïque
WO2007099553A3 (fr) Acides 1,3-dioxane-carboxyliques
WO2009125434A3 (fr) Dérivés d’oxime
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2009016498A8 (fr) Dérivés de pyrimidine et de pyridine et leur utilisation pharmaceutique et leurs compositions
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2007087548A3 (fr) Composés chimiques
WO2007144327A3 (fr) Nouveaux composés
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2008135791A8 (fr) Imidazoquinolines dotées de propriétés immuno-modulatrices
WO2007089768A3 (fr) 4-aryl-2-amino-pyrimidines ou 4-aryl-2-aminoalkyl-pyrimidines utilisées comme modulateurs de la jak-2 et leurs procédés d'utilisation
WO2008002244A3 (fr) Nouveaux composés 384
WO2008000483A3 (fr) Composés organiques
WO2008022286A3 (fr) petits inhibiteurs moléculaires de la kynurénine-3-monooxygénase
WO2007032028A8 (fr) Thiazolinones et oxazolinones et leur utilisation en tant qu'inhibiteurs de ptp1b
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2008006795A3 (fr) Composés d'indole
WO2007017728A3 (fr) Nouveaux composes heterocycliques
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2008074833A3 (fr) Composés
WO2008004100A9 (fr) Composés thérapeutiques
WO2009071691A3 (fr) Dérivés oxindoliques et leur utilisation comme médicament
MX2013003736A (es) Novedosos agonistas del receptor de la proteina g 119.

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07849663

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07849663

Country of ref document: EP

Kind code of ref document: A2